Cytek Biosciences Inc To Acquire Flow Cytometry and Imaging Business From DiaSorin- M&A Call Transcript
Hello, and thank you for standing by. Welcome to Cytek Biosciences conference call. (Operator Instructions)
I would now like to turn the conference over to your speaker for today, Dr. Wenbin Jiang, CEO. You may begin, sir.
Thank you for joining our call to discuss Cytek's acquisition of the Flow Cytometry business from Luminex Corporation. Luminex will continue to be owned by DiaSorin of Saluggia, Italy.
I want to remind everyone listening today that we will be making forward-looking statements as part of this presentation. These forward-looking statements are associated with a number of risks and uncertainties that cause -- could cause actual results to differ materially from currently anticipated results. Please read this statement to learn more about these risks and uncertainties.
I want to start by reviewing the overarching corporate growth we have at Cytek, which guide our key decision-making and operations. I'm pleased to say that the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |